Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis

2014 ◽  
Vol 45 (3) ◽  
pp. 279-287 ◽  
Author(s):  
Manabu Morimoto ◽  
Kazushi Numata ◽  
Masaaki Kondo ◽  
Satoshi Kobayashi ◽  
Shinichi Ohkawa ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Propensity Score ◽  
Propensity Score Analysis ◽  
Sorafenib Treatment ◽  
Safety And Efficacy ◽  
Score Analysis ◽  
Field Practice ◽  
Half Dose ◽  
Practice Study

scholarly journals Camrelizumab combined with sorafenib versus sorafenib alone in patients with advanced hepatocellular carcinoma: a retrospective study

2021 ◽  
Author(s):  
Qinqin Liu ◽  
Jing Li ◽  
Nan You ◽  
Ke Wu ◽  
Xuehui Peng ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Propensity Score ◽  
Propensity Score Analysis ◽  
Therapy Group ◽  
Combined Therapy ◽  
Progression Free Survival ◽  
Advanced Hepatocellular Carcinoma ◽  
Sorafenib Treatment ◽  
Advanced Hcc ◽  
Score Analysis

Abstract Background: Few studies have evaluated the efficacy and safety of immunotherapy and targeted therapy in combination. The present study aimed to compare camrelizumab plus sorafenib versus sorafenib alone in patients with advanced hepatocellular carcinoma using a propensity score analysis.Patients and methods: Between January 2019 and January 2021, a total of 100 patients with advanced HCC in the Second Affiliated Hospital of Army Medical University were retrospectively analyzed. Of the patients involved, 35 patients received combined camrelizumab plus sorafenib treatment, and 65 patients received sorafenib monotherapy. After 1:1 propensity score matching (PSM), 34 patients were included in each group. The progression-free survival (PFS), overall survival (OS), treatment response and the relevant adverse effects (AEs) were evaluated.Results: The combined-therapy group showed significantly improved overall response rate (ORR) than the sorafenib-only group (before PSM, P=0.037; after PSM, P=0.010), but no difference was noted in disease control rate (DCR) (before PSM, P=0.695; after PSM, P=1.000). The median PFS was significantly longer in the combined-therapy group than the sorafenib-only group (before PSM, P=0.041; after PSM, P=0.043). However, the two groups exhibited comparable median OS (before PSM, P=0.135; after PSM, P=0.105). Although The incidence of thrombocytopenia after PSM was significantly higher in the combined-therapy group than in the sorafenib-only group, most of the AEs could be easily controlled after treatment.Conclusion: The combination treatment of camrelizumab with sorafenib showed promising efficacy with acceptable safety for the management of advanced HCC.

Sign in / Sign up

Export Citation Format

Share Document